BridgeMD
New treatment option for Lung Cancer
Official title A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
ClinicalTrials.gov ID: NCT07354711
What this study is testing
What is 3H-10000?
3H-10000 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for lung cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- people must be willing and able to sign the ICF and to adhere to the study visit schedule and other protocol requirements.
- Male or female people aged ≥18 years at the time of signing the ICF.
- According to RECIST v1.1, there is at least one measurable lesion.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 point.
- Life expectancy of ≥3 months.
You likely can't join if
- Meningeal diseases or carcinomatous meningitis.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage every two weeks or more frequently.
- Having received treatment with other investigational drugs within 4 weeks prior to the first dose of the study drug.
- Any AEs induced by prior anti-tumor therapy having not resolved to Grade 1 or lower (except for alopecia or any other Grade 2 AEs assessed by the...
- Any corneal or retinal disease/keratopathy assessed by the investigator as of clinical significance, including but not limited to bullous/band...
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.